ICD Coverage Decision Decoded For The Street: St. Jude Waxes In CRT Glow
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical expects its implantable cardioverter defibrillator sales to grow by half in 2005, taking two percentage points of market share from Medtronic and Guidant
You may also be interested in...
St. Jude Credits Soaring ICD Sales To Its Product Line, Not Guidant Recall
St. Jude Medical says it will continue marketing its products with the assumption that Guidant's resynchronization defibrillators (CRT-D) will return to the market by the end of the third quarter
St. Jude Credits Soaring ICD Sales To Its Product Line, Not Guidant Recall
St. Jude Medical says it will continue marketing its products with the assumption that Guidant's resynchronization defibrillators (CRT-D) will return to the market by the end of the third quarter
Merlin Programmer To Lure Customers Away From CRM Rivals – St. Jude
St. Jude Medical's Merlin cardiac rhythm management device programmer is critical to the firm's ambition to reach parity with competitors Guidant and Medtronic in the CRM segment, according to the firm